Wall Street brokerages expect Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report ($1.73) earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with estimates ranging from ($1.83) to ($1.59). Ultragenyx Pharmaceutical reported earnings per share of ($1.46) during the same quarter last year, which would indicate a negative year over year growth rate of 18.5%. The company is scheduled to report its next quarterly earnings report on Monday, August 14th.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full year earnings of ($7.04) per share for the current financial year, with EPS estimates ranging from ($7.80) to ($6.52). For the next year, analysts anticipate that the business will report earnings of ($6.52) per share, with EPS estimates ranging from ($7.83) to ($5.22). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.71) by $0.08. During the same quarter in the previous year, the firm posted ($1.35) EPS.
A number of brokerages have issued reports on RARE. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Canaccord Genuity reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Monday, May 8th. Morgan Stanley lowered their price target on shares of Ultragenyx Pharmaceutical from $84.00 to $79.00 and set an “equal weight” rating for the company in a report on Monday, May 8th. Finally, Jefferies Group LLC lifted their price target on shares of Ultragenyx Pharmaceutical from $66.00 to $68.00 and gave the stock a “hold” rating in a report on Monday, May 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $82.93.
In related news, VP Theodore Alan Huizenga sold 480 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $57.46, for a total value of $27,580.80. Following the completion of the sale, the vice president now directly owns 9,366 shares in the company, valued at $538,170.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 10.10% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fortaleza Asset Management Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 980 shares during the period. Pacer Advisors Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 560 shares during the period. Strs Ohio boosted its position in shares of Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 300 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 115 shares during the period. Finally, A.R.T. Advisors LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $239,000. 95.38% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Ultragenyx Pharmaceutical (NASDAQ RARE) traded up 1.16% during mid-day trading on Tuesday, reaching $66.42. 539,473 shares of the company traded hands. The stock’s 50-day moving average is $58.65 and its 200-day moving average is $68.96. The company’s market capitalization is $2.81 billion. Ultragenyx Pharmaceutical has a 52 week low of $46.52 and a 52 week high of $91.35.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/1-73-earnings-per-share-expected-for-ultragenyx-pharmaceutical-inc-rare-this-quarter/1939122.html
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.